The EU Consultants have chart the following Roadmap for the MIBL into 3 periods namely, short term, medium term and long term.
A. Short Term (1 to 2 Years)
- Aiming to generate an ecosystem that creates trust and ensures the sustainable existence of the Mauritian biopharmaceutical industry.
- The Mauritian Biopharma Industry Model (Hub or Ecosystem).
- Priority Products and Services to address export potential, local, regional and global demands.
- Regulatory and Administrative Consolidation.
- Promotion and Commercial Efficiency.
- Capacity Building and Institutional Excellence through a platform of centres of excellence that use existing infrastructure with global standards.
- Developing Markets.
B. Medium Term (2 to 5 Years)
- Attracting investors and partnerships to materialize investments, industry infrastructure, and offer tangible products and services to replace imports and materialize potential exports.
- Staged Public and Private Investments.
- Increased offering of products and services.
- Industry Infrastructure through new centres excellence.
- Community building (Partners, Investors and Collaborators).
C. Long Term (5 Years)
- The Report forecasts that the Short term and Mid-term outcomes will allow Mauritius biopharma industry to increase export products by at least 100M. Thus setting the pace for the expansion and growth of the sector